Biotech Values

[exwannabe]

Copax trials odds.

I would like to change my estimates to :

For the CoM patents

Obviousness, double patenting, etc. : 40%
Non-infringement : 20%
Indefiniteness/Best Practice/Enablement : 5%
Inequitable conduct : 30%.

For the rest:

Obviousness etc. : 0%
Non-infringement : 80%
Indefiniteness : 10%
Inequitable conduct : 0%.


That comes out to 67% on the CoMs and 82% on the process patents, 55% overall.

I still think this is for entertainment value only. The FDA action dominates the valuation.